Compare L3Harris Technologies Inc (LHX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs BIO-TECHNE Corp — how do they compare? L3Harris Technologies Inc trades at $286.1 (market cap $53.95B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: L3Harris Technologies Inc is far larger — about 4.8× BIO-TECHNE Corp's market cap, and L3Harris Technologies Inc pays the higher dividend (1.73%). Which is the better fit depends on your goals.
| LHX | TECH | |
|---|---|---|
Market Cap | $53.95B | $11.24B |
Sector | Industrials | Health |
52-Week High | $378.48 | $72.29 |
52-Week Low | $270.21 | $43.31 |
Enterprise Value | $64.40B | $11.32B |
Dividend Yield | 1.73% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $286.67, down 0.99% on the day, with a bearish technical signal but strong fundamentals. Recent earnings beats, including Q2 2026 EPS of $3.13 versus $2.80 expected, and a record $42 billion backlog highlight operational strength. Positive news includes missile defense contracts and a dividend of $1.25 per share payable September 18, 2026.
The outlook is positive with analyst consensus at Buy and a $319.33 price target, implying 11% upside. Risks include debt levels and geopolitical dependencies, but revenue growth to $22.9 billion in 2026 and margin expansion support a constructive view for long-term investors.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
